Medical therapy to control inflammation may influence IOP outcome in SLT cases
Sep 1, 2006
By:Cheryl Guttman
San Francisco—Selective laser trabeculoplasty (SLT) is a major advance in the management of glaucoma because it safely and effectively lowers IOP without damaging or disrupting the trabecular beams.
 |
Treatment guidelines still needed, however; approach does not work for everyone
Feb 1, 2007
By:Ed Edelson
New York—The idea of using selective laser trabeculoplasty (SLT) for steroid-induced glaucoma originated with a patient's stubborn resistance to surgery, according to Janet P. Serle, MD.
|
Added benefits include fewer side effects, less expense; adherence not an issue
Jan 15, 2007
By:Lynda Charters
Las Vegas—Selective laser trabeculoplasty (SLT) is comparable to medical treatment as the initial therapy for open-angle glaucoma (OAG) or ocular hypertension, according to results of a study reported by L. Jay Katz, MD, and colleagues here at the American Academy of Ophthalmology annual meeting.
|
Prospective study finds similar safety and efficacy when comparing SLT with medical treatment
Sep 1, 2006
By:Cheryl Guttman
London, Ontario—During at least the first 12 months after treatment initiation, selective laser trabeculoplasty (SLT) and latanoprost 0.005% (Xalatan, Pfizer) are associated with equivalent efficacy and safety profiles when used as primary therapy for newly diagnosed open-angle glaucoma or ocular hypertension, according to the results of a prospective, multicenter, parallel comparison, clinical trial conducted by researchers at Ivey Eye Institute, University of Western Ontario, London.
|
| 
